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Abstract
Background: Platelet-rich plasma (PRP) preparations are a common treatment in equine osteoarthritis (OA). However,
there are controversies regarding the ideal concentration of platelets and leukocytes in these biological substances
necessary to induce an adequate anti-inflammatory and anabolic response in articular cartilage. The aims were to study
the influence of leukocyte- and platelet-rich gel (L-PRG) and pure platelet-rich gel (P-PRG) supernatants on the histological
changes of cartilage, the degree of chondrocyte apoptosis, the production of hyaluronan (HA) and the gene expression
of nuclear factor kappa beta (NFkβ), matrix metalloproteinase 13 (MMP-13), a disintegrin and metalloproteinase with
thrombospondin motifs 4 (ADAMTS-4), collagen type I alpha 1 (COL1A1), collagen type II alpha 1 (COL2A1) and cartilage
oligomeric matrix protein (COMP) in normal cartilage explants (CEs) challenged with lipopolysaccharide (LPS).
Results: Overall, 25 % L-PRG supernatant (followed in order of importance by, 50 % P-PRG, 25 % P-PRG and 50 % L-PRG)
represented the substance with the most important anti-inflammatory and anabolic effect. 25 % P-PRG supernatant
presented important anabolic effects, but it induced a more severe chondrocyte apoptosis than the other evaluated
substances.
Conclusions: 25 % L-PRG supernatant presented the best therapeutic profile. Our results demonstrate that the biological
variability of PRP preparations makes their application rather challenging. Additional in vivo research is necessary to know
the effect of PRP preparations at different concentrations.
Keywords: Platelet-rich plasma, Cartilage explants, Chondrocyte apoptosis, Catabolic/anabolic gene expression, Growth
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Background
Osteoarthritis (OA) is a chronic inflammatory disease that
affects middle aged and older people worldwide [1]. This
disease also affects horses and other animal species, which
causes economic losses by diminishing the athletic poten-
tial of the affected animals and through the chronic use of
anti-inflammatory drugs and nutraceuticals [2–4]. Thus,
the horse is an important animal model to study both the
pathophysiological mechanisms and the experimental
treatments of OA [5, 6].
There are several extrinsic factors associated with OA
development such as joint repetitive trauma, obesity, joint
infection and osteochondrosis, amongst others [4]. During
the OA developmental process, there are structural (histo-
logical) changes indicating the severity or degree of affect-
ation of the articular cartilage [7]. This includes increased
chondrocyte necrosis, cluster (complex chondrone) for-
mation, fibrillation/fissuring, focal cell loss and diminished
uptake of safranin-O fast green (SOFG) stain [8]. Further-
more, another important histological change associated
with OA is chondrocyte apoptosis, which leads to loss of
resident cells in the articular cartilage and results in severe
alterations such as impaired extracellular matrix (ECM)
remodelling [9]. This phenomenon has been described in
both human and animal models of OA [10, 11]. Chondro-
cyte apoptosis could be detected by caspase-3 expression
or terminal deoxynucleotidyl transferase dUTP nick end
labelling (TUNEL) staining [12].
Together with the OA histological changes are several
joint molecular alterations characterized by nuclear factor
kappa beta (NFkβ) upregulation [13] that subsequently
upregulates several catabolic and proinflammatory cyto-
kines for cartilage such as interleukin-1 (IL-1) and tumour
necrosis factor alpha (TNF-α), matrix metalloproteinases
(MMPs - e.g. MMP-13), aggrecanases (i.e. a disintegrin and
metalloproteinase with thrombospondin motifs 4 -
ADAMTS-4), inducible synthases of nitric oxide and cyclo-
oxygenase type 2 [14]. Consequently, a proinflammatory
molecular milieu produces histological alterations in cartil-
age and induces molecular changes with clinical accom-
panying indicators such as pain and synovial effusion [4].
In the initial OA stages, joint tissues (e.g. cartilage) act
by upregulating anabolic gene expression to induce car-
tilage ECM anabolism and to increase the synthesis of
collagen type II alpha 1 (COL2A1), cartilage oligomeric
matrix protein (COMP) and hyaluronan (HA) amongst
other anabolic ECM components. However, as the OA
progresses, the local expression and production of colla-
gen type I alpha 1 (COL1A1) appears as a poor anabolic
response by the osteoarthritic cartilage [15, 16].
Platelet-rich plasma (PRP) has been used as a therapy
for OA in humans [17–19] and animals [20–23]. The ra-
tionale for the therapeutic use of PRP stems from the
fact that platelets (PLTs) (but also white blood cells –
WBC-) contained in PRP represent an important au-
tologous source of some growth factors (GFs), which
include transforming growth factor beta 1 (TGF-β1),
platelet derived growth factor isoform BB (PDGF-BB)
[24, 25], and other anti-inflammatory cytokines such as
interleukin 4 (IL-4) and the receptor antagonist of IL-1
(IL-1ra) [26, 27], which are implicated in the anabolic
characteristics of OA [4, 28]. Furthermore, in vitro
studies have revealed that PDGF-BB downregulates
NFkβ [29, 30] and increases the proliferation of chon-
drocytes [29, 31], whereas TGF-β1 increases the cartil-
age extracellular matrix (ECM) synthesis and promotes
the differentiation of stem cells in chondrocytes [32].
Currently, there is controversy about which PRP prep-
aration is ideal for the intra-articular treatment of pa-
tients with OA [33, 34]. Some in vitro [35–37] and
clinical studies have suggested that leukoreduced PRP
(also known as pure PRP [P-PRP]) preparations have
better anabolic and anti-inflammatory effects for OA
treatment than leukoconcentrate PRP (L-PRP) prepara-
tions, whereas other studies have described similar posi-
tive effects for both preparations [32, 38, 39].
Recently, we demonstrated in an in vitro system of
cartilage inflammation that 50 % L-PRP releasate pro-
duced a more sustained temporal concentration of
growth factors and anti-inflammatory cytokines than
both 25 % L-PRP and P-PRP releasates and 50 % P-PRP
releasate in relation to the concentration in culture
media [40]. However, there is no information regarding
the effects of these substances on the histology or ECM
cartilage gene expression.
The study presented here shows complementary and
novel information for the anabolic, anti-inflammatory ef-
fect of two supernatant concentrations (25 and 50 %)
from both P-PRP and L-PRP preparations on equine car-
tilage explants (CEs) challenged with lipopolysaccharide
(LPS). This research evaluates and compares the influ-
ence of both platelet-rich gel (PRG) supernatants on the
histological changes of cartilage, the degree of chondro-
cyte apoptosis, the production of HA and the gene ex-
pression of NFkB, MMP-13, ADAMTS-4, COL1A1,
COL2A1 and COMP in an in vitro system of cartilage
inflammation and degeneration.
The hypothesis of this study is that L-PRG superna-
tants at a lower concentration (25 %) have better anti-
inflammatory and anabolic effects than both PRG
supernatants at the higher 50 % concentration and P-
PRG supernatant at 25 % concentration in CEs chal-
lenged with LPS.
Methods
This study was approved by the committee on animal ex-
perimentation of the Universidad de Caldas, Manizales,
Colombia.
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Samples
Cartilage samples from the metacarpophalangeal joints
from six horses, aged 4 to 9 years, were included in this
study. The samples were taken from horses that were
free from musculoskeletal disease and euthanised by a
pentobarbital intravenous overdose for other medical
reasons. All metacarpophalangeal joints were radio-
graphed and macroscopically evaluated to exclude
horses with OA-associated joint changes.
L-PRP and P-PRP preparation
Venous blood from one clinically healthy mare was used
in order to avoid the great variability in the GF and cyto-
kine concentrations in the PRG supernatants used in the
experiments. Platelet concentrates were obtained through
a manual double centrifugation tube method [41] that was
previously validated and used clinically in horses with OA
[21]. Blood was drawn from jugular venipuncture and im-
mediately deposited in 4.5 mL tubes with sodium citrate
solution (BD Vacutainer®, Becton Drive, Franklin Lakes,
NJ, USA). After centrifugation at 120 × g for five minutes,
the first 50 % of the top supernatant plasma fraction, adja-
cent to the buffy coat, was collected. This fraction was
centrifuged at 240 × g for five minutes, and then the bot-
tom quarter of the fraction was collected [41]. This frac-
tion was considered as L-PRP. The upper plasma fraction
was considered as P-PRP (Fig. 1). Whole blood and both
PRP preparations were analysed for PLT and WBC counts
using an impedance-based haematology device (Celltac-α
MEK 6450, Nihon Kodhen, Japan).
Both PRP preparations were activated with calcium glu-
conate (Ropsohn Therapeutics Ltda®, Bogotá, Colombia)
(ratio 1:10) and incubated at 37 °C for 1 h until clot retrac-
tion occurred. Fresh L-PRG and P-PRG supernatants were
used to add to the culture media at two concentrations
(25 % and 50 %). Aliquots of both PRG supernatants ob-
tained were frozen at -86 °C for later quantification of
PDGF-BB, TGF-β1 and HA.
Cartilage explants culture and LPS challenge
Cartilage samples were obtained aseptically, and circular
4 mm diameter explants were obtained using a dispos-
able biopsy punch (KAI Medical, Solingen, Germany).
CEs were dissected from the articular surface without
calcified cartilage layers and washed in phosphate-
buffered saline.
CEs were stabilised in Dulbecco’s Modified Eagle
Medium (DMEM) (high glucose, 4500 mg/L) with L-
glutamine and sodium bicarbonate and free of sodium
pyruvate (DMEM, Lonza Group Ltd, Basel, Switzerland)
and supplemented with streptomycin (100 μg/mL) and
penicillin (100 μg/mL) without the addition of serum.
Cultures were incubated in a 5 % CO2 and water satu-
rated atmosphere for 24 h and then replaced with fresh
Fig. 1 Schematic workflow of the experiments of the study
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culture media. At this time point (24 h), the CEs were
challenged with 100 ng/mL of LPS (Sigma-Aldrich, St
Louis, MO, USA) to induce inflammatory/catabolic
damage of the cartilage [42, 43].
Study design
A total of 30 CEs were obtained from each horse. The
study design included the evaluation of six experimental
groups using five CEs per group from each horse as fol-
lows: one CE healthy control group without LPS and with-
out addition of any PRG supernatant, one CE control
group challenged with LPS and without addition of any
PRG supernatant, and four CE groups cultured with L-
PRG and P-PRG supernatants at two different concentra-
tions (25 % and 50 %). After 1 h of incubation, L-PRG and
P-PRG supernatants were added in order to obtain con-
centrations at 25 and 50 %. All CE groups were cultured
at 96 h, after which the culture media were frozen in ali-
quots at -86 °C for later determination of HA concentra-
tion by ELISA. Furthermore, the CEs were deposited in
buffered formaldehyde for histological analysis or in an
RNA conserving solution (RNAlater, Life Technologies,
Carlsbad, CA, USA) for quantitative gene expression of
NFkB, MMP-13, ADAMTS-4, COL1A1, COL2A1 and
COMP. The schematic diagram (Fig. 1) summarises the
study design and methodology.
ELISA analysis
L-PRG and P-PRG supernatants and culture media at
96 h were used to determine the concentration of
PDGF-BB, TGF-β1 and HA via ELISA in duplicate. All
proteins were assayed using commercial ELISA devel-
opment kits from R&D Systems (Minneapolis, MN,
USA). PDGF-BB (Human PDGF-BB DuoSet, DY220)
and TGF-β1 (Human TGF-β1 DuoSet, DY240E) were
determined using human antibodies because there is a
high sequence homology between these proteins in
humans and horses [44, 45]. Furthermore, these kits
have been used for the same purposes in other equine
PRP studies [24, 25]. HA (Hyaluronan, DuoSet,
DY3614) was determined using a multispecies detection
ELISA kit. Standards provided for each ELISA kit were
used to prepare each standard curve following the man-
ufacturers’ instructions. Absorbance readings were per-
formed at 450 nm.
H&E histology evaluation
CEs were dehydrated in serial alcohol concentrations,
fixed in wax blocks, cut into 3 μm slices and stained with
either haematoxylin and eosin (H&E) or safranin O stains.
The outcome parameters evaluated were: (1) chondrocyte
necrosis, (2) cluster (complex chondrone) formation, (3)
fibrillation/fissuring, (4) focal cell loss and (5) safranin-O
stain uptake. All preparations were analysed using a light
microscope in a 40× magnification following the OARSI
histopathology initiative for histological assessments of
osteoarthritis in the horse [8] (Table 1).
These variables were quantified using a 0–4 scale,
with 0 being normal and 4 being abnormal (Table 1).
Thus, a totally normal CE would score 0 and a max-
imally abnormal CE would score 15 [8]. Three sec-
tions randomly selected from each sample were
evaluated blindly and the average score was used for
comparison.
TUNEL assay for chondrocyte apoptosis
TUNEL staining was performed to detect DNA strand
breakage using a commercial kit for cell and tissues
(TACS TdT-Blue Label In situ Apoptosis Detection Kit,
Trevigen, Inc., Gaitherburg, MD, USA). Briefly, the CEs
were washed and dehydrated in serial alcohol concentra-
tions, fixed in wax blocks and cut into 3 μm slices. The
tissue sections were deparaffinised with xylene and etha-
nol and washed with PBS. The samples were covered
with 50 μl of proteinase K solution and incubated for
15 min at 37 °C in a humidity chamber. The samples
were washed with PBS and covered with 50 μl of label-
ling reaction mix. After this, the samples were immersed
in a stop buffer solution for 5 min at room temperature
to stop labelling reaction and once more washed twice
with PBS for 2 min at room temperature. The samples
were covered with 50 μl of antibody solution and incu-
bated for 30 min at 37 °C then washed with PBS and
covered with 50 μl of TACS Blue Label™ (Trevigen, Inc.,
Gaitherburg, MD, USA). These samples were washed
with deionised water and counterstained with nuclear
fast red. The controls were treated similarly except that
terminal deoxynucleotidyl transferase was substituted by
distilled water [46].
After the reaction, stained chondrocytes (grey-black)
were analysed under a light microscope. Chondrocyte
apoptosis was scored by a semiquantitative approach
using a 0-4 scale, where 1 = 6–25 % of chondrocyte
apoptosis; 2 = 26–50 % of chondrocyte apoptosis; 3 =
51–75 % of chondrocyte apoptosis and 4 = 76–100 % of
chondrocyte apoptosis [47].
Molecular evaluation
CE samples were pulverised in liquid nitrogen and
mixed with TRIzol reagent (Life Technologies, Carlsbad,
CA, USA) for 5 min. The samples were centrifuged for
10 min at 10,000 × g, and the supernatant was mixed
with 20 % chloroform (volume/volume) and then centri-
fuged for 15 min at 12,000 × g. The aqueous phase of
the samples was removed and transferred to special col-
umns (PureLink RNA Mini Kit, Life Technologies,
Carlsbad, CA) for RNA extraction according to the man-
ufacturer’s instructions. RNA concentrations were
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measured using a spectrophotometer (Nanodrop 2000,
Thermo Scientific, Wilmington, DE, USA). Samples
were diluted to a concentration of 5 ng/μL of RNA.
The samples were assayed for quantitative gene expression
levels in a qRT-PCR device (StepOnePlus Real-Time PCR
System, Life Technologies, Carlsbad, CA, USA) using a
SuperScript III platinum SYBR Green One-Step qRT-PCR
kit (Life Technologies, Carlsbad, CA, USA). Primers for
NFkB, MMP-13, ADAMTS-4, COL1A1, COL2A1, COMP
and GAPDH (glyceraldehyde 3-phosphate dehydrogenase)
were designed and validated in the Colombian Centre for
Bioinformatics and Computational Biology (BIOS) (Table 2).
The relative change in gene expression was determined
via the comparative 2-ΔΔCT method [48]. GAPDH was
used as the internal control (housekeeping gene), and car-
tilage samples from all horses that were not incubated
with any treatment were used as reference samples.
Statistical and data analysis
The statistical analysis was performed with SPSS 19.0 soft-
ware (IBM, Chicago, IL, USA). The Shapiro–Wilk test was
used to assess the fit of the data set to a normal distribu-
tion (goodness of fit). All the parameters evaluated, except
CE histology and apoptosis scores, demonstrated a normal
distribution (p > 0.05). However, these data were normal-
ised by using a transformation log (Y).
Platelet and WBC counts in whole blood and both
PRP preparations were evaluated through a one-way
analysis of variance (ANOVA), followed by a Tukey test.
PDGF-BB, TGF-β1 and HA concentrations from both
PRG supernatants were compared using a t-non-paired
test. A generalised lineal model (GLM), followed (when
necessary) by a Tukey test, was used for comparing HA
concentrations in culture media and gene expression at
96 h. The HA concentrations in fresh culture media with
PRG supernatants at 1 h and 96 h were compared using
a t-paired test. A p < 0.05 was accepted as statistically
significant for all tests. Data are presented as mean ±
mean standard error (m.s.e).
Results
Cell, growth factor and HA in L-PRP/L-PRG and P-PRP/P-PRG
PLT counts were significantly (p < 0.05) different be-
tween whole blood, L-PRP and P-PRP, with the lowest
Table 1 Microscopic grading system for articular cartilage
histology [8]
Articular cartilage
Outcome parameter Score Description
Chondrocyte
necrosis*
0 Normal section without necrosis
1 No more than one necrotic cell
located near the articular surface
per 20x objective
2 1e2 necrotic cells located near the
articular surface per 20x objective
3 2e3 necrotic cells located near the
articular surface per 20x objective
4 3e4 necrotic cells located near the
articular surface per 20x objective
Cluster (complex
chondrone) formation
0 No cluster formation throughout section
1 Two chondrocytes (doublets) within
same lacunae along superficial aspect
of the articular cartilage section
2 2e3 chondrocytes (doublets & triplets)
within same lacunae along superficial
aspect of the articular cartilage section
3 3e4 chondrocytes within same lacunae
along superficial aspect of the articular
cartilage section
4 Greater than four chondrocytes within
same lacunae along superficial aspect
of the articular cartilage section
Fibrillation/fissuring 0 No fibrillation/fissuring of the articular
cartilage surface
1 Fibrillation/fissuring of the articular
cartilage restricted to surface and
superficial zone
2 Fissuring that extends into the middle
zone
3 Fissuring that extends to the level of
the deep zone
4 Fissuring that extends into the deep
zone
Focal cell loss* 0 Normal cell population throughout
the section
1 A 10e20% area of acellularity per 20x
field
2 A 20e30% area of acellularity per 20x
field
3 A 40e50% area of acellularity per 20x
field





1 Less than 25 % loss of staining
characteristics
Table 1 Microscopic grading system for articular cartilage
histology [8] (Continued)
2 25e50% loss of staining characteristics
3 50e75% loss of staining characteristics
4 Greater than 75 % loss of staining
characteristics
*Chondrocyte necrosis is used to grade presence of lacunae with necrotic nuclei
still present compared to focal cell loss which is most likely an extension of the
pathologic change but lacunae or nuclei are no longer present
Carmona et al. BMC Veterinary Research  (2016) 12:135 Page 5 of 13
concentration for P-PRP (98.7 00 ± 4.600 PLT/μL),
followed by whole blood (125.900 ± 3.400 PLT/μL) and
L-PRP (312.800 ± 19.600 PLT/μL). WBC counts were
also significantly different between the evaluated groups,
with a higher concentration for L-PRP (35.100 ± 3.500
WBC/μL), followed by whole blood (8.300 ± 3.700
WBC/μL) and P-PRP (110 ± 40 WBC/μL). TGF-β1 con-
centration was similar between L-PRG (1676.3 ±
312.4 pg/mL) and P-PRG (1356.9 ± 20.8 pg/mL). PDGF-
BB had a significantly (p < 0.05) higher concentration in
L-PRG (3053. 8 ± 956.7 pg/mL) when compared to P-PRG
(372.7 ± 79.6 pg/mL). HA concentration was significantly
(p < 0.05) higher in L-PRG supernatant (4.3 ± 1.7 pg/mL)
in comparison to P-PRG supernatant (1.1 ± 0.21 pg/mL).
H&E histology evaluation
Chondrocyte necrosis scores were significantly (p <
0.05) worse (higher) for CEs from the control group
with LPS and those treated with 25 % L-PRG and
50 % P-PRG supernatants when compared to CEs of
the control group and those treated with 50 % LPRG
and 25 % P-PRG supernatants (Fig. 2a). Cluster for-
mation was significantly higher for CEs from the con-
trol group plus LPS when compared to the rest of
the CE groups evaluated. This histology parameter
was similar among CEs from the healthy control
group and those treated with both L-PRG superna-
tants and 25 % P-PRG supernatant, whereas CEs
treated with 50 % P-PRG supernatant presented a sig-
nificantly worse score than the aforementioned CE
groups (Fig. 2b).
Fibrillation/fissuring scores were significantly (p < 0.05)
higher in both control groups, although there was a statis-
tical trend (p = 0.10) showing CEs of the healthy control
group with lower score in comparison to CEs of the con-
trol group treated with LPS. In general, CEs treated with
all PRG supernatants presented significantly (p < 0.05)
lower scores. However, CEs treated with 50 % L-PRG and
25 % P-PRG supernatants were significantly lower than
CEs of healthy control group (Fig. 2c).
Focal cell loss scores were significantly (p < 0.05)
worse for the CEs of control group treated with LPS
and those treated with 50 % P-PRG supernatant. CEs
from the healthy control group and those treated with
both 25 % PRG supernatants presented significantly (p
< 0.05) lower scores than the rest of the CE groups
(Fig. 2d). SOFG stain uptake score were significantly (p
< 0.05) worse for CEs treated with 50 % L-PRG super-
natant, followed by CEs of the control group challenged
with LPS and both 25 % PRG supernatants. The best
score for this histology parameter was found in CEs of
the healthy control group and those treated with 50 %
P-PRG supernatant (Fig. 2e).
The general histology total score was significantly (p <
0.05) higher in CEs of the control group challenged with
LPS when compared to CEs of the healthy control
group and those treated with both L-PRG and 25 % P-
PRG supernatant. In general, CEs treated with both
25 % PRG supernatants showed significantly (p < 0.05)
better general histology score than the rest of the
groups evaluated (Fig. 2f ).
TUNEL assay for chondrocyte apoptosis
No chondrocyte apoptosis was detected in CEs of the
healthy control group and those treated with both 50 %
PRG supernatants. However, this cellular phenomenon
was detected (and it was significantly higher [p < 0.05])
in CEs of the control group challenged with LPS and
those treated with both 25 % PRG supernatants;
although, the score for this parameter was apparently
lower for those CEs treated with 25 % L-PRG super-
natant (Fig. 2g).
Concentration of HA in culture media at 1 h and 96 h
At 1 h, HA concentrations varied significantly (p < 0.05)
between all PRG supernatant groups evaluated. At
96 h, HA was released by all CE groups. However,
Table 2 Genes and sequence of primers evaluated in the study
Targeted genes Primer sequences (5'- > 3') Product size
(bps)
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 6 Forward TCCCTGCTTCTACTGGTGCT Reverse TGACAAAGTGGTCGTTGAGG 306
NFkβ, nuclear factor of kappa light polypeptide gene
enhancer in B-cells-like 1
Forward CGATTTCGATATGGCTGTGA Reverse CACCTTCTTCAGCTCCTTGG 399
MMP 13, matrix metallopeptidase 13 (collagenase 3) 7 Forward GCATTCAAAAAGGCCTTCAA Reverse GGAAGCACAAAGTGGCTTTT 356
ADAMTS 4, metallopeptidase with thrombospondin
type 1 motif 4
Forward TGTCAGCTTGGTGGTGACTC Reverse GTTGAAGACATGGCCCAGTT 322
COL1A1, collagen, type I, alpha 1 11 Forward AGCCAGCAGATCGAGAACAT Reverse CTGGCCACCATACTCGAACT 309
COL2A1, collagen, type II, alpha 1 6 Forward primer ACGTCCAGATGACCTTCCTG Reverse primer
GTCCACACCAAATTCCTGCT
326
COMP, cartilage oligomeric matrix protein 21 Forward CCACGTGAATACGGTCACAG Reverse TAGGAACCAGCGGTAGGATG 301
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the CE group cultured with 25 % P-PRG supernatant
presented the highest significant (p < 0.05) HA release
in comparison with the CE control group and the
other CE PRG-treated groups. Notably, HA concen-
trations were different between CE PRG treated
groups at 1 h and 96 h (Fig. 3).
Fig. 2 Means (±standard error of the mean [s.e.m]) of the cartilage histology and chondrocyte apoptosis scores. a Chondrocyte necrosis. b Cluster
formation. c Fibrillation/fissuring. d Focal cell loss. e SOFG stain uptake. f Total histology score. g Chondrocyte apoptosis. a-bDifferent lowercase letters
denote significant (p ˂ 0.05) differences between the groups evaluated by the Tukey test
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Gene expression
NFkB gene expression was significantly (p < 0.05) in-
creased in CEs from the control group challenged with
LPS in comparison to the rest of the CE groups evalu-
ated. NFkB gene expression was significantly (p < 0.05)
diminished in CEs treated with both 25 % PRG superna-
tants and 50 % P-PRG supernatant in comparison to the
CEs from the healthy control group and those treated
with 50 % P-PRG (Fig. 4).
CEs from the healthy control group and all PRG super-
natant treatments presented a significant (p < 0.05) decrease
of MMP-13 expression (Fig. 5). However, 25 % L-PRG
supernatant induced a lesser expression of this gene in CEs
when compared to CEs treated with 50 % P-PRG super-
natant (p < 0.05). No significant differences were noticed
for the expression of this catabolic gene in the CEs from
the healthy control group and those treated with 50 % L-
PRG, and 25 and 50 % P-PRG supernatants (Fig. 5).
All PRG supernatant treatments significantly (p < 0.05) de-
creased ADAMTS-4 gene expression in CEs when com-
pared to CEs of both control groups (Fig. 6). Furthermore,
CEs from the healthy control group and all PRG super-
natant treatments showed significant (p < 0.05) COL1A1
gene downregulation when compared to CEs of the control
group challenged with LPS (Fig. 7). L-PRG supernatants at
different concentrations significantly (p < 0.05) diminished
the COL2A1 gene expression in CEs in comparison to CEs
treated with both P-PRG supernatant concentrations and
the control group. Notably, there were not significant differ-
ences between these last three groups and CEs from the
healthy control group for COL2A1 gene expression
(Fig. 8). However, although this gene expression was sta-
tistically (p = 0.09) similar among CEs from both control
groups, COL2A1gene expression was apparently higher in
CEs from the healthy control group than in CEs chal-
lenged only with LPS (Fig. 8).
COMP gene expression was significantly (p < 0.05) di-
minished in CEs from the control group challenged with
LPS and those treated with the 50 % L-PRG supernatant
Fig. 3 Means (± s.e.m) of HA concentration in culture media from
cartilage explant (CE) groups at 1 h and 96 h. a-b Different lowercase
letters denote significant (p < 0.05) differences between the groups
evaluated by the Tukey test over the same period of time. * Denotes
significant differences between the same variable at different time
periods by the t-paired test
Fig. 4 Means (± s.e.m) of NFkB gene expression in CE groups at
96 h. a-b Different lowercase letters denote significant (p < 0.05)
differences between the groups evaluated by the Tukey test
Fig. 5 Means (± s.e.m) of MMP-13 gene expression in CE groups at 96 h
a-b Different lowercase letters denote significant (p< 0.05) differences
between the groups evaluated by the Tukey test
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in comparison to CEs treated with both the 25 % PRG
supernatants and the 50 % P-PRG supernatant. CEs from
the healthy control group and those treated with both
25 % PRG supernatants presented similar increased
COMP gene expression. However, CEs treated with both
25 % PRG supernatants demonstrated a significantly
higher CE gene expression when compared to CEs
treated with 50 % P-PRG supernatant (Fig. 9).
Discussion
Diverse PRP effects on cells and tissues are well recog-
nised as depending on their varying preparations [38].
Thus, the molecular profile of a PRG supernatant is as-
sociated with the type and quantity of WBCs and PLTs
initially present in PRP [25, 28]. However, after PRP is
activated in a joint, it becomes a fibrin mesh or PRG that
releases growth factors and cytokines and acts as an im-
mune node inside the joint [49]. We currently believe
that the cell ratio (PLT:WBC) in PRP is not as critical as
the GF:GF or GF:cytokine ratios and concentrations
Fig. 6 Means (± s.e.m) of ADAMTS-4 gene expression in CE groups
at 96 h. a-b Different lowercase letters denote significant (p < 0.05)
differences between the groups evaluated by the Tukey test
Fig. 7 Means (± s.e.m) of COL1A1 gene expression in CE groups at
96 h. a-b Different lowercase letters denote significant (p < 0.05)
differences between the groups evaluated by the Tukey test
Fig. 8 Means (± s.e.m) of COL2A1 gene expression in CE groups at
96 h. a-b Different lowercase letters denote significant (p < 0.05)
differences between the groups evaluated by the Tukey test
Fig. 9 Means (± s.e.m) of COMP gene expression in CE groups at
96 h. a-b Different lowercase letters denote significant (p < 0.05)
differences between the blood component groups obtained with
the same anticoagulant by the Tukey test
Carmona et al. BMC Veterinary Research  (2016) 12:135 Page 9 of 13
released into the joint fluid [50]. However, we also wish
to clarify that this assumption could possibly be valid for
the use of PRP in joints and not for the infiltrative use
of this substance in tendons, ligaments or muscles,
where not only is the growth factor concentration im-
portant, but also the fibrin mesh to allow growth factor
storage, cell migration and cell proliferation [51].
Strong debates continue about the ideal PLT:WBC
ratio and concentration in PRP [51]. Currently, there are
several studies indicating that plasma with a poor quan-
tity of PLTs and negligible WBs could be the best “PRP”
preparations to treat OA and other musculoskeletal
pathologies [35, 36, 52]. However, a recent in vitro study
described molecular positive effects for several commer-
cial kits which have concentrates at different PLT:WBC
ratios and are used for OA treatment [39].
Thus, we decided to conduct an independent study to
evaluate the effect of two different PRP preparations (ob-
tained by a homemade lab method) at different concentra-
tions on cartilage histology, chondrocyte apoptotic scores,
HA release and catabolic and anabolic gene expression of
CEs challenged with LPS. Exposure of CEs to LPS resulted
in marked changes in the expression of genes involved in
matrix formation and degradation as well as inflammation
of which many were reduced by the addition of both PRG
supernatants at different concentrations.
The use of LPS for inducing cartilage inflammation/
degeneration is a classical methodological approach to
perform diverse in vitro studies by simulating a system
of inflammatory/degenerative arthropaty [42, 43, 53]; al-
though, the use of recombinant IL-1β to induce in vitro
articular cartilage degradation could be more suitable
[54, 55]. However, it is important to clarify that the cel-
lular receptors for LPS and IL-1β are closely interlinked
and described as the TLR-IL-1 receptor (IL-1R) super-
family of receptors. When activated they induce a series
of intercellular signalling pathways that converge on the
activation of the transcription NFkB resulting in pro-
inflammatory cytokine expression [55, 56].
It is important to mention that the evaluation of the
anti-inflammatory effect of PRG supernatants by measur-
ing the relative expression of the NFkB gene in the present
study represents a very limited approach to understanding
the activity signalling of this important inflammatory
process [57]. However, an in vitro study in human chon-
drocytes revealed that activated PRP induced the expres-
sion and production of inhibitor-ĸBα (IĸBα) (directly
mediated by hepatocyte growth factor), which is respon-
sible for the inhibition of the transcription of NFkB [58].
This finding has also been consistent for gingival fibro-
blasts and alveolar osteoblasts challenged with LPS and
cultured with PRP preparations [59].
Notably, LPS challenge induced important structural (de-
generative) changes accompanied with chondrocyte
apoptosis in CEs, which were reverted or ameliorated in di-
verse degrees by PRG supernatants. However, the general
histology score was significantly lower (better) for CEs
treated with PRG supernatants, and some individual out-
come parameters, such as chondrocyte necrosis, focal cell
loss and SOFG uptake, were affected by some of these
substances.
Chondrocyte necrosis was mostly observed in CEs
treated with 25 % L-PRG and 50 % P-PRG supernatants.
This finding could indicate that these substances at these
specific concentrations were not able to reverse the cata-
bolic effect mediated by endotoxin in CEs. Furthermore,
it is also important to consider that both 25 % PRG
supernatants presented chondrocyte apoptosis reaction
similar to those observed in CEs from the control group
challenged with LPS; although, CEs treated with 25 % P-
PRG supernatant presented the highest score for this
parameter. This last finding could possibly indicate that
this substance at lower concentration is not able to
reverse the cartilage catabolic effects of LPS and can in-
duce additional chondrocyte apoptosis.
Focal cell loss was more evident for both 50 % PRG su-
pernatants, possibly due to that chondrocytes being able
to migrate inside the CEs towards the periphery through a
chemotactic attractive stimulus in the culture media [60],
such as the milieu of growth factors released from PRP
[61–63]. In contrast, another explanation to demonstrate
the cause of focal cell loss in the groups of CEs treated
with higher concentrations of PRG supernatants could be
attributed to chondrocyte necrosis or even chondrocyte
apoptosis [64]. However, this lack of significant increase of
these parameters occurred only for CEs treated with 50 %
P-PRG supernatant, which could indicate that P-PRG
preparations were not chondroprotective.
The SOFG uptake score was higher in CEs treated
with 50 % L-PRG and 25 % P-PRG supernatants, and ap-
parently this parameter was worst for CEs treated with
50 % L-PRG supernatant. This parameter is associated
with the structural content of proteoglycans in the cartil-
age ECM [8], which indicate the quality and integrity of
this structure. It is important to consider that 50 % L-
PRG supernatant also induced downregulation of ana-
bolic ECM genes, such as COL2A1 and COMP. Taken
together, these histology and molecular findings indicate
that higher concentrations of L-PRP preparations could
be deleterious for osteoarthritic cartilage. One pitfall of
the present research was that the release or accumula-
tion of proteoglycans was not measured in the culture
media of CEs. However, we consider that the combin-
ation of histology parameters and gene expression could
be valid indicators for the degree of affection of ECM of
the CEs of this study.
The combination of the general histology score, chon-
drocyte apoptosis findings, HA release to the culture
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media and the catabolic and anabolic cartilage ECM
gene expression demonstrated that all PRG supernatants
are “biosubstances” with mixed biological effects. In gen-
eral, all PRG supernatants presented a potential anti-
inflammatory effect and decreased the catabolic effects
of LPS on CEs at the cellular and molecular level. How-
ever, the overall analysis of our results indicates that
25 % L-PRG supernatant (followed in order of import-
ance by 50 % P-PRG, 25 % P-PRG and 50 % L-PRG) rep-
resented the substance with the most important anti-
inflammatory and anabolic effect with lower affection of
CEs at the histology level. Furthermore, 25 % P-PRG
supernatant presented important anabolic effects, but it
induced a more severe chondrocyte apoptosis than the
other of the evaluated substances. This detrimental cell
effect limits the potential clinical use of this substance at
this concentration.
The present results can be complemented with the
previous findings obtained by us in two in vitro stud-
ies, in which the production of anti-inflammatory and
catabolic cytokines was measured in the culture
media of synovial membrane explants (SME) [27] and
CEs [40] challenged with LPS over 48 h and 96 h. In
general, 25 % L-PRG and 50 % L-PRG supernatants
presented the best anabolic and anti-inflammatory
profile. However, in both studies, 25 % L-PRG super-
natant produced a most significant reduction of TNF-
α production and a total higher production of IL-1ra
over time than 50 % L-PRG [27, 40].
Currently, we use 3-5 mL doses of PRP to treat fetlock
osteoarthritis in horses with a body weight of 300-
450 kg. This PRP volume has also been used for other
researches with good results [22]. Notably, the complete
volume capacity for an equine fetlock joint has been cal-
culated at 12.5 ± 1.0 mL [65]. Thus, if the PRP volume
used is adjusted in relation to the volume capacity of
this specific joint [65], the effective concentration of
PRP in clinical conditions could be near to 40 %, without
considering the additional volume of synovial fluid (2-
2.5 mL), which could represent a final PRP/synovial fluid
concentration of 40-60 %. In line with this, the PRP dose
for this joint could possibly be adjusted at 25 % using
between 1.5-2.0 mL. However, this hypothesis should be
probed in patients with osteoarthritis or experimentally
induced synovitis.
Our findings are in line with the results of Cavallo et
al. [39] and Kreuz et al.[38], who found diverse and posi-
tive effects for L- and P-PRP preparations in human
osteoarthritic chondrocytes and subchondral mesenchy-
mal progenitor cells. Conversely, our results are different
from other in vitro studies [34–36], which have con-
cluded that only P-PRP preparations induce an anabolic
effect in cartilage and L-PRP preparations only induce
an opposite (catabolic) joint state.
This study had several limitations. First, this is an in
vitro study, which does not reflect the exact biological
phenomena occurring in the osteoarthritic joint. How-
ever, this in vitro system of cartilage inflammation and
degeneration could be useful to demonstrate that L-
and P-PRG supernatants could act in function of their
concentration and could have different mechanisms of
action to induce cartilage joint anabolism and, poten-
tially, diminish pain and inflammation. Another limita-
tion of this study was that blood of only one animal
was used to produce the PRG supernatants evaluated to
avoid the great variability in the CE responses to several
PRP preparations. This situation is not practical in clin-
ical conditions because autologous PRP should be used.
However, the response of each patient in particular will
depend in some measure on the concentration of the
cells’ proteins in PRP.
Conclusions
This study demonstrates that both L- and P-PRP prepara-
tions at different concentrations can induce different anti-
inflammatory, anti-catabolic, anabolic and even catabolic
responses in an in vitro system of cartilage inflammation
and degeneration.
Apparently, 25 % L-PRG supernatant presented the
best therapeutic profile when compared to the other
PRP preparations examined, because it presented anti-
inflammatory and anabolic effects with minimal cellular
and structural changes in CEs. Our results once more
demonstrate that the biological variability of PRP prepa-
rations makes their application rather challenging. Add-
itional studies in animal models and in patients with OA
should be performed to know the in vivo effect of PRP
preparations at different concentrations.
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